相关临床试验
63
24 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
12
19.1%
已完成
12
19.1%
Enrolling By Invitation
1
1.6%
尚未招募
11
17.5%
招募中
19
30.2%
终止
3
4.8%
Unknown
4
6.3%
撤回
1
1.6%
暂无批准数据
- The NORTH STAR VNP Cancer Trials Centre early phase unit has officially opened at Royal North Shore Hospital, backed by a transformative $20 million philanthropic gift from the Poche family. - Initial trials are underway for patients with lung and brain cancer, with plans to expand to a broader range of cancers, reducing the need for patients to travel long distances for care. - The facility partners with Memorial Sloan Kettering Cancer Centre in New York on international clinical trials, giving Australian patients access to breakthrough medications and generating crucial multi-centre data. - NSW Health provided ward space and infrastructure, with the unit also expected to foster partnerships with hospitals in rural and regional communities across New South Wales.
- The NSW Government has awarded $800,000 in Clinical Trials Fellowship grants to improve cancer clinical trial access for rural and regional patients across the state. - Three grants worth $200,000 each focus on regional initiatives including remote trial delivery frameworks, teletrials, and engagement with underrepresented populations. - A fourth $200,000 grant supports the ACTIvate study for anaplastic thyroid cancer immunotherapy, building on global evidence to address unique treatment challenges. - The funding is part of Cancer Institute NSW's annual $5 million investment in cancer clinical trials, aiming to ensure equitable access regardless of geographic location.
- Doron Therapeutics has dosed the first patients in a Phase 3 clinical trial of MOTYS (PTP-001), an investigational biologic therapy for knee osteoarthritis that has received FDA FastTrack and RMAT designations. - The randomized, placebo-controlled trial will enroll approximately 300 patients across multiple sites to evaluate pain and functional improvements for up to 12 months following a single injection. - MOTYS is derived from donated placental tissues and designed with a multifactorial mechanism targeting inflammation and tissue damage pathways in osteoarthritis. - The therapy addresses a significant unmet medical need, as osteoarthritis remains the leading cause of pain and disability worldwide with limited treatment options.
- Aethlon Medical successfully treated the first three patients in its Hemopurifier cancer trial at Australian hospitals, with all participants completing 4-hour treatments without device deficiencies or immediate complications. - The company received regulatory approval from India's Central Drugs Standard Control Organization to initiate a similar oncology study at Medanta Medicity Hospital. - Preclinical data demonstrated 98.5% removal of platelet-derived extracellular vesicles, supporting potential applications in multiple diseases including cancer, Long COVID, and autoimmune conditions. - The trial protocol was expanded to include patients receiving combination therapies with Pembrolizumab or Nivolumab, reflecting current immunotherapy treatment practices.
- Aethlon Medical successfully treated a second patient with its investigational Hemopurifier device in an Australian clinical trial targeting solid tumors resistant to anti-PD-1 therapies. - Both patients in the first cohort completed 4-hour treatments without device deficiencies or immediate complications, with safety data to be reviewed by an independent Data Safety Monitoring Board. - The approximately 18-patient trial aims to evaluate whether removing tumor-derived extracellular vesicles can improve response rates to pembrolizumab or nivolumab, which currently show lasting responses in only 30-40% of patients. - The Hemopurifier holds FDA Breakthrough Device designation and is designed to bind and remove extracellular vesicles implicated in cancer metastasis and immunotherapy resistance.
- Strand Therapeutics announced preliminary Phase 1 data for STX-001, a self-replicating mRNA therapy encoding IL-12, showing favorable safety and encouraging anti-tumor activity in 22 patients with checkpoint inhibitor-refractory solid tumors. - The trial demonstrated multiple RECIST responses including a confirmed complete response and partial responses, with systemic immune activation observed even in non-injected lesions across multiple tumor types. - STX-001 was well-tolerated up to 300 µg with dose-dependent increases in plasma IL-12 and IFN-γ, representing the first clinical validation of Strand's programmable mRNA platform technology. - The company plans to advance to Phase 2 monotherapy trials and initiate combination studies with checkpoint inhibitors, while developing STX-003, an intravenous version, for 2026 patient dosing.
• Phase 3 INTEGRATE IIa trial demonstrates regorafenib extends median overall survival to 4.5 months versus 4.0 months with placebo in refractory advanced gastric/GEJ cancer patients. • Treatment with regorafenib significantly delayed disease progression and quality-of-life deterioration, with a progression-free survival of 1.8 months compared to 1.6 months for placebo. • The study validates regorafenib's potential as a treatment platform, supporting its investigation in combination therapies including ongoing trials with nivolumab and chemotherapy.
